^
Association details:
| Biomarker: | LOC101927285-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation
Published date:
10/21/2020
Excerpt:
A 61-year-old male patient was simultaneously diagnosed with lung adenocarcinoma...The lung adenocarcinoma...harbored two distinct types of ALK translocation, LOC101927285-ALK and TPM3-ALK, respectively. The patient was therefore given an endobronchial cryotherapy and ALK inhibitor crizotinib. The tumors showed durable response however the left lung adenocarcinoma relapsed at 17th month post crizotinib treatment. Tissue re-biopsy on the resistant tumor revealed an ALK exon 23 C1156Y missense mutation in addition to LOC101927285-ALK mutation.
DOI:
10.4143/crt.2020.952
